CBS - The 17th Left Main & Coronary Bifurcation Summit, CBS2025

CBS 2019

CBSMD教育中心

HOME
CBS 2019
At CBS

General Information

Left Main & Coronary Bifurcation Summit (CBS) was founded in 2006 as a think tank dedicated to the treatment of left main and coronary bifurcation lesions. CBS aims to improve cardiological care by refreshing fundamental researches, clinical trials, yearly published guidelines, emerged ideas and case-based discussion.

Association and Affiliations
- Organized by
  
  Nanjing Heart Center
  
  Asian Bifurcation Club (ABC)
  
  Nanjing First Hospital, Nanjing Medical University
- Co-organized by
  
  Chinese Society of Cardiology (CSC)
  
  Capacity Building and Continuing Education Center,National Health and Family Planning Commission (CBCEC)
  
  American Society for Cardiovascular Angiography and Interventions (SCAI)
  
  Asian Heart Society (AHS)
Contact Us
- Registration Administration of Domestic Representatives
  
  Hongjuan Peng : +86-13913895477
  
  Haimei Xu +86-13914736846
  
  cbsnj@cbsmd.cn
- Registration Administration of Overseas Representatives
  
  Ling Lin : +86 (25) 52271398
  
  +86-13951884596
  
  cbs@cbsmd.cn
- Management of Challenging Cases
  
  Yingying Zhao :+86-13815408517
  
  sub@cbsmd.cn
Address

CBS2019 Congress Secretariat, Nanjing First Hospital, Building No.9 68# Changle Road, Nanjing, China

210006
FACULTY
FACULTY

General Chairman
Congress Chairman
Course Directors International Faculty Domestic Faculty Hong Kong and Taiwan Faculty Members of Academic Committee
Education Center

Education Center

• Online Education (For more customized user interface with self-defined collection of research papers and education resources.)

• CBS Education Resource

• CBSMD Scientific Library
SCIENTIFIC LIBRARY

SCIENTIFIC LIBRARY

Research Paper

> Acute Coronary Syndrom

> ASCVD Prevention

> Bifurcation Stenting

> Cardio-Oncology

> Congestive Heart Failure

> DAPT Duration

> Drug Coated Balloon

> Fractional Flow Reserve

> IVUS Guidance

> Optical Coherence Tomography

> Pulmonary Hypertension

> Rotational Atherectomy

> Shear Stress

> Stenting Left Main

> Transcatheter Aortic Valve Replacement

> Percutaneous LAA Occlusion

> Mitral/Tricuspid Valvular Disease

> Other Relevant Articles

Recommended Paper

Management of Acute Myocardial Infarction During the COVID-19 Pandemic

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic

ACC Clinical Bulletin Focuses on Cardiac Implications of Coronavirus (COVID-19)

< >

HOME | SCIENTIFIC LIBRARY | Shear Stress

Shear Stress

Prediction of progression of coronary artery disease and clinical outcomes using vascular profiling of endothelial shear stress and arterial plaque characteristics: the PREDICTION Study Role of endothelial dysfunction in determining angina after percutaneous coronary intervention: Learning from pathophysiology to optimize treatment High Coronary Shear Stress in Patients With Coronary Artery Disease Predicts Myocardial Infarction Angiographic derived endothelial shear stress: a new predictor of atherosclerotic disease progression Flow-Regulated Endothelial S1P Receptor-1 Signaling Sustains Vascular Development Low Endothelial Shear Stress Predicts Evolution to High-Risk Coronary Plaque Phenotype in the Future: A Serial Optical Coherence Tomography and Computational Fluid Dynamics Study Evolving understanding of the heterogeneous natural history of individual coronary artery plaques and the role of local endothelial shear stress TAVI Represents an Anti-Inflammatory Therapy via Reduction of Shear Stress Induced, Piezo-1-Mediated Monocyte Activation

Sort by hits |<< 1 2 3 >>|

Original Research

JOURNAL：CBSMD Article Link

HFpEF最新科学探索之抑制一氧化氮合酶

CBSMD

Pre-reading

心力衰竭是仅有的几种发病率持续增加的心血管疾病之一, 两种疾病亚型正在世界范围内蔓延开来：一种为射血分数降低心力衰竭（heart failure with reduced ejection fraction, HFrEF），治疗方法包括药物、装置和移植；另一种射血分数保留的心力衰竭（heart failure with preserved ejection fraction, HFpEF），目前因缺乏充分代表HFpEF复杂疾病进展的相关实验模型，现今的治疗选择主要针对症状、心血管基础疾病和合并症、心血管疾病危险因素，采取综合性治疗手段，仍旧处于摸石头过河的阶段, 而诊疗方向的最新探索或为HFpEF的治疗带来了新的曙光。

2018年4月“Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry”注册研究数据指出，HFpEF患者接受永久性心脏起搏置入治疗的发生率及患者群特征。

传统的右心室心脏起搏器或可导致左心室机电不同步，并加重左心室收缩功能障碍和心衰，“Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction”使用CHARM-Preserved, I-PRESERVE和TOPCAT研究数据，对其中置入心脏起搏器的患者进行了预后随访，揭示了该类型心脏起搏器对HFpEF患者不良临床预后的影响。

2019年4月“Novel percutaneous interventional therapies in heart failure with preserved ejection fraction: an integrative review”阐述了HFpEF的病理生理机制并集中介绍了经皮介入治疗HFpEFd的最新疗法。

既往HFpEF心力衰竭模型侧重于提高一氧化氮合酶（nitric oxide synthase, NO）酶的水平, 而疾病临床表现常与该假设相反，NO酶水平在HFpEF患者中常表达过高。2019年4月10日美国德克萨斯大学西南医学中心研究Hill JA研究团队发表的“Nitrosative stress drives heart failure with preserved ejection fraction”在细胞水平上研究了利用新病理生理模型获得的结果，并将其与人类细胞进行比较，研究结果提示抑制一氧化氮合酶有望治疗HFpEF型心力衰竭，提示受iNOS影响的IRE1α-XBP1通路的失调或是HFpEF心肌细胞功能障碍的一个重要机制。

>CBS

CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

CBS 2019

CBS 2019 FACULTY

Education Resource

CBSMD Scientific Library